We are live on
!
Find out more
SAM
Senzar Asset Management Portfolio holdings
AUM
$34.7M
1-Year Est. Return
0.56%
This Fund
S&P 500
This Quarter
Est. Return
+9.33%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$899M
AUM Growth
+$212M
(+31%)
Cap. Flow
+$125M
Cap. Flow
% of AUM
13.86%
Top 10 Holdings %
Top 10 Hldgs %
65.2%
Holding
49
New
13
Increased
20
Reduced
8
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bausch Health
BHC
|
+$146M |
| 2 |
AGN
Allergan plc
AGN
|
+$37.1M |
| 3 |
Universal Health Services
UHS
|
+$16.5M |
| 4 |
Centene
CNC
|
+$15.4M |
| 5 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$9.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$44.9M |
| 2 |
Amgen
AMGN
|
+$28.7M |
| 3 |
NVRO
NEVRO CORP.
NVRO
|
+$28M |
| 4 |
Cigna
CI
|
+$23.4M |
| 5 |
STJ
St Jude Medical
STJ
|
+$22.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.72% |
| 2 | Financials | 6.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MNTA
26
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $8.04M | 0.89% |
+542,091
| New | +$9.07M |
|
27
DaVita
DVA
$15.5B
| $6.61M | 0.73% |
+94,800
| New | +$6.94M |
|
|
SEM
28
DELISTED
Select Medical
SEM
| $5.86M | 0.65% |
+913,152
| New | +$5.71M |
|
|
FPRX
29
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $5.62M | 0.63% |
+135,535
| New | +$4.54M |
|
|
ZGNX
30
DELISTED
Zogenix, Inc.
ZGNX
| $5.57M | 0.62% |
377,600
+306,300
| +430% | +$4.12M |
|
31
Enanta Pharmaceuticals
ENTA
$362M
| $5.41M | 0.6% |
+163,986
| New | +$5.34M |
|
|
AVDL
32
DELISTED
Avadel Pharmaceuticals
AVDL
| $5.39M | 0.6% |
+441,500
| New | +$6.88M |
|
|
ESPR
33
DELISTED
Esperion Therapeutics
ESPR
| $4.98M | 0.55% |
+223,700
| New | +$5.64M |
|
34
Rigel Pharmaceuticals
RIGL
$723M
| $4.59M | 0.51% |
151,350
+13,791
| +10% | +$418K |
|
|
AGRX
35
DELISTED
Agile Therapeutics
AGRX
| $3.77M | 0.42% |
+193
| New | +$3.05M |
|
|
VXRT
36
DELISTED
Vaxart
VXRT
| $3.71M | 0.41% |
173,680
+15,825
| +10% | +$347K |
|
|
ARNA
37
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $3.69M | 0.41% |
194,409
+17,710
| +10% | +$361K |
|
38
Rocket Pharmaceuticals
RCKT
$343M
| $3.51M | 0.39% |
+77,400
| New | +$3.37M |
|
|
NDRM
39
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $3.44M | 0.38% |
201,700
+145,700
| +260% | +$2.84M |
|
|
SIEN
40
DELISTED
Sientra, Inc.
SIEN
| $3.44M | 0.38% |
58,085
+33,656
| +138% | +$1.75M |
|
|
ADYX
41
DELISTED
Adynxx Inc
ADYX
| $2.17M | 0.24% |
16,902
+1,541
| +10% | +$263K |
|
|
42
Amgen
AMGN
$209B
| – | – |
-207,400
| Closed | -$28.7M |
|
|
43
Cigna
CI
$78.4B
| – | – |
-173,600
| Closed | -$23.4M |
|
44
Standard BioTools
LAB
$342M
| – | – |
-310,587
| Closed | -$2.52M |
|
45
MiMedx Group
MDXG
$630M
| – | – |
-416,361
| Closed | -$4.02M |
|
46
Orthofix Medical
OFIX
$492M
| – | – |
-134,984
| Closed | -$4.56M |
|
|
XOMA
47
DELISTED
Xoma
XOMA
| – | – |
-116,355
| Closed | -$1.75M |
|
|
ACHN
48
DELISTED
Achillion Pharmaceuticals
ACHN
| – | – |
-619,000
| Closed | -$4.28M |
|
|
XNPT
49
DELISTED
XENOPORT, INC.
XNPT
| – | – |
-2,150,090
| Closed | -$7.46M |
|
Similar funds
BCP
PRHC
NAM
GG
SM
BC
SCPM
FAM
Senzar Asset Management's Q4 2015 Portfolio in Review
As of Q4 2015, Senzar Asset Management held 49 positions worth $899M, up 31% from $687M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Senzar Asset Management deployed $125M of net new capital in Q4 2015, opening 13 new positions and adding to 20 existing holdings. Its largest new stake was Bausch Health: 1,299,056 shares worth $132M.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 84% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Viatris, an estimated $44.9M trimmed.
- Senzar Asset Management's largest Q4 2015 buy was Bausch Health: 1,299,056 shares worth $132M.
- Senzar Asset Management added most to Acorda Therapeutics in Q4 2015, an estimated $8.72M increase.
- Senzar Asset Management's biggest Q4 2015 reduction was Viatris, cutting an estimated $44.9M.
- Senzar Asset Management fully exited Amgen in Q4 2015, selling an estimated $28.7M.
- Senzar Asset Management's ten largest holdings make up 65% of its $899M portfolio in Q4 2015.
- Senzar Asset Management opened 13 new positions and closed 8 in Q4 2015.
- Senzar Asset Management's portfolio value rose 31% quarter-over-quarter to $899M.
Based on Senzar Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.